Yousif A. Lucinian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yousif A. Lucinian has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Matthieu Pelletier-Galarneau
Department of Medical Imaging, Institut de Cardiologie de Montréal, Montréal, Canada
3 shared publications - Patrick Martineau
Department of Molecular Imaging and Therapy, BC Cancer, Vancouver, BC, Canada
3 shared publications - Daniel Juneau
Nuclear medicine division, Centre Hospitalier de l’Université de Montréal, Montréal, Canada
1 shared publication - Francois Harel
Department of Medical Imaging, Montreal Heart Institute, Montreal, Canada
1 shared publication - François Harel
Department of Nuclear Medicine, Montreal Heart Institute and Université de Montréal, Montreal, Quebec, Canada
1 shared publication - Geneviève Giraldeau
Department of Medicine, Institut de Cardiologie de Montréal, Montréal, Canada
1 shared publication
Latest Publications
- 27 May 2026
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- p. 1-13
18F-fluorodeoxyglucose positron emission tomography and rest myocardial perfusion imaging in non-granulomatous myocarditis
Purpose Data on the use of fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) in non-granulomatous myocarditis are limited, and no study has evaluated the diagnostic performance of combined FDG-PET and rest myocardial perfusion imaging (rMPI). Methods We conducted a multicenter prospective observational feasibility study of patients who underwent combined FDG-PET/CT with rMPI as well as cardiac magnetic resonance (CMR) for suspected myocarditis. When available, endomyocardial biopsy (EMB) established the diagnosis according to consensus criteria. Otherwise, the final adjudicated clinical diagnosis served as the reference standard. All patients had a minimum follow-up of 12 months following PET imaging. Results Twenty-five patients were included, of whom 18 (72%) were diagnosed with myocarditis. FDG-PET and rMPI demonstrated a sensitivity/specificity of 61%/100%, and 59%/71%, respectively. Inter-reader agreement for FDG-PET was excellent (κ = 0.84, 95% CI 0.62–1.00). The combination of FDG-PET and rMPI yielded a sensitivity of 82% (95% CI: 50–93%) and a specificity of 71% (95% CI: 29–96%). Late gadolinium enhancement (LGE), excluding isolated subendocardial patterns, showed a sensitivity/specificity of 72%/57%. Spatial agreement between rMPI perfusion defects and LGE on CMR was modest (κ = 0.35, 95%CI: 0.23–0.47). Conclusion Combining FDG-PET with rMPI may be a feasible imaging modality for detecting non-granulomatous myocarditis by capturing both inflammatory and fibrotic components across different disease stages.
- 27 May 2026
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- p. 1-13
18F-fluorodeoxyglucose positron emission tomography and rest myocardial perfusion imaging in non-granulomatous myocarditis
Purpose Data on the use of fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) in non-granulomatous myocarditis are limited, and no study has evaluated the diagnostic performance of combined FDG-PET and rest myocardial perfusion imaging (rMPI). Methods We conducted a multicenter prospective observational feasibility study of patients who underwent combined FDG-PET/CT with rMPI as well as cardiac magnetic resonance (CMR) for suspected myocarditis. When available, endomyocardial biopsy (EMB) established the diagnosis according to consensus criteria. Otherwise, the final adjudicated clinical diagnosis served as the reference standard. All patients had a minimum follow-up of 12 months following PET imaging. Results Twenty-five patients were included, of whom 18 (72%) were diagnosed with myocarditis. FDG-PET and rMPI demonstrated a sensitivity/specificity of 61%/100%, and 59%/71%, respectively. Inter-reader agreement for FDG-PET was excellent (κ = 0.84, 95% CI 0.62–1.00). The combination of FDG-PET and rMPI yielded a sensitivity of 82% (95% CI: 50–93%) and a specificity of 71% (95% CI: 29–96%). Late gadolinium enhancement (LGE), excluding isolated subendocardial patterns, showed a sensitivity/specificity of 72%/57%. Spatial agreement between rMPI perfusion defects and LGE on CMR was modest (κ = 0.35, 95%CI: 0.23–0.47). Conclusion Combining FDG-PET with rMPI may be a feasible imaging modality for detecting non-granulomatous myocarditis by capturing both inflammatory and fibrotic components across different disease stages.
- 28 February 2025
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 50 (7) , e443-e444
FDG-PET/CT for Effective Staging of Disseminated Blastomycosis
We present the case of a 67-year-old man undergoing immunosuppressive therapy with known pulmonary blastomycosis who presented with knee swelling and fever. FDG-PET/CT performed to exclude septic arthritis revealed increased uptake within the right epididymis and multiple osteoarticular, cutaneous, and subcutaneous sites. Cultures obtained from bronchoalveolar lavage, urine, right knee arthrocentesis, and subcutaneous tissue all demonstrated Blastomyces dermatitidis, compatible with disseminated blastomycosis (DB). To the best of our knowledge, this is the first case of DB in a human subject documented by FDG-PET. This case showcases FDG-PET as a potentially sensitive imaging modality in staging blastomycosis multiorgan involvement, aiding in identifying culture sites by revealing clinically and radiologically unsuspected foci of infection.
- 28 February 2025
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 50 (7) , e443-e444
FDG-PET/CT for Effective Staging of Disseminated Blastomycosis
We present the case of a 67-year-old man undergoing immunosuppressive therapy with known pulmonary blastomycosis who presented with knee swelling and fever. FDG-PET/CT performed to exclude septic arthritis revealed increased uptake within the right epididymis and multiple osteoarticular, cutaneous, and subcutaneous sites. Cultures obtained from bronchoalveolar lavage, urine, right knee arthrocentesis, and subcutaneous tissue all demonstrated Blastomyces dermatitidis, compatible with disseminated blastomycosis (DB). To the best of our knowledge, this is the first case of DB in a human subject documented by FDG-PET. This case showcases FDG-PET as a potentially sensitive imaging modality in staging blastomycosis multiorgan involvement, aiding in identifying culture sites by revealing clinically and radiologically unsuspected foci of infection.
- 31 May 2023
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 30 (6) , 2490-2500
FDG-PET/CT and rest myocardial perfusion imaging to predict high-degree atrioventricular block recovery in cardiac sarcoidosis
- 31 May 2023
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 30 (6) , 2490-2500
FDG-PET/CT and rest myocardial perfusion imaging to predict high-degree atrioventricular block recovery in cardiac sarcoidosis
- 14 October 2022
- Published by Springer Nature
- p. 353-383
Cardiovascular FDG-PET Atlas of Cases